Thomas Heiser practices general corporate and securities law, with a focus on emerging companies, venture capital funds and public companies. Thomas also represents clients who are at the cutting edge of using novel technologies including blockchain, distributed networks, cryptocurrencies and digital assets.
Andreessen Horowitz Closes $53 Million Series A Investment in Hippocratic AI
March 19, 2024
Cooley advised Andreessen Horowitz (a16z) on its $53 million Series A investment in Hippocratic AI, a California-based company building a safety-focused large language model for healthcare. This funding round brings Hippocratic AI to a $500 million valuation. Partner Josh Seidenfeld led the Cooley team advising the Bio + Health VC fund of a16z, a Silicon Valley venture capital firm that invests in bold founders, innovators and entrepreneurs building the future through technology.
VC Firm a16z Closes $20 Million Series A Investment in knownwell
December 20, 2023
Cooley advised a16z on its $20 million Series A investment in knownwell, which provides in-person and virtual primary care and metabolic healthcare. Partner Josh Seidenfeld led the Cooley team advising a16z, a venture capital firm in Silicon Valley that invests in bold founders, innovators and entrepreneurs building the future through technology.
Cooley advised Lightspeed Venture Partners in its investment in Nirvana Insurance’s $57 million Series B financing. Nirvana Insurance is a provider of commercial insurance services intended to help fleets to improve safety and reduce costs. Lawyers Thomas Heiser and Nima Agah participated on the Cooley team.
Cooley advised Andreessen Horowitz (a16z) in its investment in Story Protocol’s $54 million financing. Story Protocol is a developer of a Web3 technology designed to revolutionize how narrative universes are created. Lawyers Nancy Wojtas, Thomas Heiser and J.P. Mohler led the Cooley team.
Genesis Therapeutics Closes Oversubscribed $200 Million Series B
August 21, 2023
Cooley advised Andreessen Horowitz (a16z) Bio + Health Tech Investments, an a16z fund with a focus on biotechnology and healthcare technology, in connection with Genesis Therapeutics’ oversubscribed $200 million Series B financing.
